Companies/US/EYPT

EYEPOINT, INC.

Last · —$3.01-0.06 (-1.95%)live · yahoo · 1h ago
Vol 3.16M ≈ 9.50M
Market cap$259.50M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session

Issuer

Legal nameEYEPOINT, INC.
HQUnited States (US)
ListingUS EYPT
ISINUS30233G2093
SectorHealthcare
IndustryPharmaceuticals
SIC3826
CurrencyUSD
Entity registrysec:0001314102
CIK0001314102
LinkedIn
Employees214
AddressEyePoint Pharmaceuticals, Inc. 480 Pleasant Street 02472, Watertown +617 926 5000
Headline financial metrics
Revenue$31.4M
Operating income$-243.4M
Net income$-232.0M
Free cash flow$-243.4M
Operating margin-776.0%
Net margin-739.4%
Return on equity-75.8%
Period2025
Loading chart…

OpenFilings analyst

Our analyst

10-K · 2026-03-05

From latest 10-K · 2026-03-05

  • Sbc Revenue High
  • Operating Cf Burn
  • Net Margin Sharply Negative
  • Cash Conversion Weak
  • Cash Runway Low
  • Accumulated Deficit High
  • Rd Intensity High

Red flags

  • Sbc Revenue High — SBC/Revenue 88.8%
  • Operating Cf Burn — Negative operating cash flow
  • Net Margin Sharply Negative — Net margin -739.4%
  • Cash Conversion Weak — Cash conversion (CFO/Rev) -765.4%
  • Cash Runway Low — Cash runway ~0.4 years
  • Accumulated Deficit High — Accumulated deficit / equity 361%
  • Rd Intensity High — R&D/Revenue 704.6%

Upcoming earnings

1 event
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.92
Est. revenue
252,500

Press & signals

3 of 5 recent
  • GlobeNewswire

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • GlobeNewswire

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • GlobeNewswire

    EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
2026-09-102026-09-100
2026-08-202026-08-240
2026-08-182026-08-180
2026-08-172026-08-170